Abstract 248P
Background
Children receiving palliative care face unique physical and psychosocial needs. Parents may turn to complementary medicines (CM); however, related studies are limited. This study examined the pattern of CM use among pediatric patients with cancer and non-cancer conditions receiving palliative care.
Methods
Between April 2021 and June 2022, parents of patients (<19 years old) receiving palliative care were recruited from 3 hospitals in Hong Kong. They completed a structured survey on sociodemographic data, CM use, and the child’s symptom burden (Rotterdam Symptoms Checklist). Clinical data were collected from health records. Differences in characteristics were compared among CM users (with cancer or non-cancer conditions) and non-users.
Results
We recruited 61 patients (60.7% male; mean age=10.4 years). Overall, 68.9% reported CM use, most commonly Chinese herbal medicine (39.3%) and massage/TuiNa (34.4%). Among the 24 patients with cancer, 62.5% were CM users; they were older at cancer diagnosis than non-users (p<0.001). Non-oral CM approaches, especially acupuncture, were less popular among patients with cancer than non-cancer patients (29.2% vs 64.9%, p=0.01). Among CM users, patients with cancer had higher physical symptom distress than non-cancer users (22.0 vs 17.3, p<0.01). More parents of children with cancer consulted their doctors before using CM than non-cancer users (73.3% vs 33.3% p=0.03), and considered CM to be effective in relieving nausea, vomiting and indigestion symptoms (p<0.05). Most parents (73%) spent ≥USD 130 on CM monthly. Among cancer patients, the most common reason for not using CM was the lack of information (55.6%). Multivariable analyses showed that older parents (aOR=1.15, 95%CI=1.02-1.31) were more likely to use CM, while children who received bone marrow transplant were less likely to use CM (aOR=0.16, 95%CI=0.03-0.73). Most parents (82.5%) supported CM integration, especially Chinese medicine and acupuncture, into palliative care service.
Conclusions
Two-third of surveyed pediatric patients with cancer receiving palliative care used CM regularly. Future work should explore integrating CM approaches into palliative programs for symptom management and psychological support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03